<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795712</url>
  </required_header>
  <id_info>
    <org_study_id>2126 CE</org_study_id>
    <nct_id>NCT05795712</nct_id>
  </id_info>
  <brief_title>'Real Life' Monitoring of COPD no ICS Patients</brief_title>
  <acronym>COPDnoICS</acronym>
  <official_title>'Real Life' Monitoring of COPD Patients According to the 2017 GOLD Recommendations: Role of Bronchial Inflammation in Patient Management.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituti Clinici Scientifici Maugeri SpA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituti Clinici Scientifici Maugeri SpA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study will be to assess in patients with mild-to-moderate COPD the role of&#xD;
      inflammation in the patient's therapeutic management and follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have already shown that the risk of severe exacerbations in patients with COPD is&#xD;
      associated with eosinophilic inflammation (1) and that patients with this type of&#xD;
      inflammation have an increased risk of exacerbations if ICS administration is discontinued&#xD;
      (2), but this indication does not appear in the latest GOLD recommendations to date.&#xD;
&#xD;
      The aim of the study will be to evaluate in patients with mild-to-moderate COPD the role of&#xD;
      induced sputum and peripheral inflammation in the patient's therapeutic management and&#xD;
      follow-up. For this purpose, the investigators will assess inflammation at the bronchial and&#xD;
      systemic level by induced sputum and haemochrome at time 0 (recruitment), after 6,12, 18 and&#xD;
      24 months after therapy administration according to the updated 2017 GOLD recommendations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Actual">March 9, 2023</completion_date>
  <primary_completion_date type="Actual">September 7, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants which introduced ICS therapy after 24 month of follow up</measure>
    <time_frame>24 months</time_frame>
    <description>The aim of our study will be to evaluate in patients with mild-to-moderate COPD the role of inflammation in the patient's therapeutic management and follow-up.</description>
  </primary_outcome>
  <enrollment type="Actual">53</enrollment>
  <condition>COPD</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Therapy Change from Baseline</intervention_name>
    <description>The patient will be followed up from the point of view of therapy according to symptoms and flare-ups irrespective of systemic or peripheral eosinophil assessment</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      induced sputum blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with COPD diagnosis in therapy with LABA or LAMA or LABA/LAMA&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COPD diagnosis according to GOLD 2017 recommendations in clinical stability phase&#xD;
&#xD;
          -  Post bronchodilator FEV1 ≥50 and ≤80&#xD;
&#xD;
          -  Both smoker and ex-smoker&#xD;
&#xD;
          -  Patients on LABA or LABA/LAMA therapy&#xD;
&#xD;
          -  Patients also on ICS therapy discontinued at least 30 days after enrolment&#xD;
&#xD;
          -  Patient able to cooperate with the required procedures&#xD;
&#xD;
          -  Patient who has signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Acute respiratory episode treated with antibiotics and/or steroids in the lower 4&#xD;
             weeks prior to enrolment&#xD;
&#xD;
          -  Patients on roflumilast therapy&#xD;
&#xD;
          -  Any exacerbation of COPD within 1 month after visit 1. A patient must not have had any&#xD;
             hospitalisation for COPD within 6 months prior to visit 1.&#xD;
&#xD;
          -  Comorbidities. History or current evidence of a clinically significant comorbidity or&#xD;
             history of a positive test for HIV, hepatitis B or hepatitis C.&#xD;
&#xD;
          -  History of adverse reactions including immediate or delayed hypersensitivity to any&#xD;
             beta2-agonists,&#xD;
&#xD;
          -  sympathomimetic drugs or any intranasal, inhaled or systemic corticosteroid therapy&#xD;
             known or suspected sensitivity to the components of the inhalers used in the study&#xD;
             (e.g. lactose in dry powder inhalers).&#xD;
&#xD;
          -  Use of immunosuppressive drugs within 12 weeks prior to visit 1 and during the study,&#xD;
             including use of systemic corticosteroids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Istituti Clinici Maugeri Pneumologia</name>
      <address>
        <city>Tradate</city>
        <state>Lombardia</state>
        <zip>21049</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 9, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 21, 2023</last_update_submitted>
  <last_update_submitted_qc>March 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituti Clinici Scientifici Maugeri SpA</investigator_affiliation>
    <investigator_full_name>RicercaTradate</investigator_full_name>
    <investigator_title>Professor Antonio Spanevello</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

